Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1104704

	registered interest
	date	25/03/2019
	answering body	Department for Education
	answering dept id	60
	answering dept short name	Education
	answering dept sort name	Education
	hansard heading	STEM Subjects: Skilled Workers
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Education, what steps his Department is taking to tackle the skills gap in STEM subjects.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	236376
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>To address the shortage of science, technology, engineering and mathematics (STEM) skills, the Department is encouraging more students into STEM education and training, at all stages from primary school to higher education. As part of the Industrial Strategy, the Government has committed substantial spending on mathematics, digital and technical education to increase the take-up and better teaching of STEM subjects in schools. For example, the Department is funding a new £84 million programme to improve computing teaching and participation, and the Advanced Maths Premium which aims to support schools and colleges in tackling some of the financial barriers to increase participation in post-16 maths.</p><p> </p><p>The Department is committed to tackling the gender imbalance in STEM subjects, and has invested in programmes to address female participation, particularly in subjects like computing and physics. This includes the Stimulating Physics Network which has a specific strand focusing on increasing the number of girls’ in physics A level. A Gender Balance in Computing pilot programme will also be launched this year to identify practical interventions that schools (at all stages, excluding post-16) can implement to improve girls’ participation in computing.</p><p> </p><p>The Department is improving careers advice in schools so that young people are aware of the high quality options available for both technical and academic routes into STEM and that they have access to information about the variety of careers that STEM pathways have to offer. STEM activities, including employer talks and work visits, are built into school career programmes and the Careers &amp; Enterprise Company funds opportunities for young people to meet a wide range of STEM employers.</p><p> </p> answering member constituency Bognor Regis and Littlehampton answering member printed Nick Gibb question first answered 02/04/2019 16:54:44 answering member 111 label Biography information for Nick Gibb
	tabling member	4131 label Biography information for Jim Shannon

1104703

	registered interest
	date	25/03/2019
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Research: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, if he will support a targeted capacity building approach to his Department’s funding of research and development.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	236375
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>As part of the Government’s commitment to increase overall investment in R&amp;D to 2.4% of GDP by 2027, we are supporting capacity building in a number of ways.</p><p> </p><p>For example, we are building research talent, increasing investment in early career researchers through a £900 million Future Leaders Fellowship programme. In addition, we are boosting capacity in artificial intelligence through new AI Masters and AI Centres for Doctoral Training, delivering 1,000 additional PhDs in AI and Turing AI Fellows.</p><p> </p><p>We are also boosting capacity in specific places across the UK, building on R&amp;D strengths through our Strength in Places Fund. Twenty-four ambitious projects from pharmaceuticals to aerospace, and transport to the creative economy, are to receive early-stage funding to develop full-stage bids that could lead to significant economic growth in places across the country. For example, Artemis Technologies is leading a bid to build a facility in Belfast Harbour that will focus on the decarbonisation of maritime transportation.</p> answering member constituency Kingswood answering member printed Chris Skidmore question first answered 02/04/2019 13:03:19 answering member 4021 label Biography information for Chris Skidmore
	tabling member	4131 label Biography information for Jim Shannon

1104692

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many oncology patients have been registered to receive treatment through the NHS in each year since 2010.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	236365
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236367 236369 question first answered 02/04/2019 11:24:26 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1104693

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Professions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many (a) nurses and (b) doctors are specifically employed within the oncology speciality.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	236366
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS Digital publishes Hospital and Community Health Services workforce statistics. These include staff working in hospital trusts and clinical commissioning groups, but not staff working in primary care, local authorities or other providers.</p><p> </p><p>The latest NHS Digital workforce statistics show that as at 30 December 2018 there are 1,317 doctors with a speciality in clinical oncology and 985 doctors with a speciality in medical oncology. The figures include all doctors working in the specialty of oncology such as consultants, associate specialists, specialty doctors, doctors in training etc.</p><p> </p><p>The latest NHS Digital workforce statistics show that as at 30 December 2018 there are 2,093 nurses who work in an area of ‘clinical oncology’ and 1,237 nurses who work in an area of ‘medical oncology’. This data represents nurses who are working in services related to oncology, rather than nurses with specialist training in oncology.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/04/2019 11:43:26 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1104694

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much the NHS spent on providing oncological treatment in each year since 2010.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	236367
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236365 236369 question first answered 02/04/2019 11:24:27 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1104696

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many IT systems are used within oncological treatment in the NHS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	236369
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236365 236367 question first answered 02/04/2019 11:24:27 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1104708

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether NHS England plans to continue to fund the NICE commissioning support programme until the capacity of the NICE appraisal programme is increased to enable the routine assessment of all new medicines.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	236380
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>NHS England is continuing the commissioning support work programme in 2019/20, with the expectation that the National Institute for Health and Care Excellence will have extended its capacity by 2020.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/04/2019 11:44:12 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1104709

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Priorities Advisory Group
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which clinical policies awaiting review by the Clinical Priorities Advisory Group involve the use of the NICE commissioning support programme.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	236381
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>The clinical policies awaiting review by the Clinical Priorities Advisory Group, which involve the use of the National Institute for Health and Care Excellence (NICE) commissioning support work programme are as follows:</p><p>- Chenodeoxycholic acid and cholic acid for treating inborn errors in primary bile acid synthesis;</p><p>- Telotristat for treating carcinoid syndrome;</p><p>- Bictegravir-emtricitabine-tenofovir alafenamide for treating HIV-1;</p><p>- Idebenone for treating Leber hereditary optic neuropathy;</p><p>- Canakinumab for treating periodic fever syndromes;</p><p>- Emicizumab for bleed prevention in severe and moderate haemophilia A without inhibitors;</p><p>- Dolutegravir with rilpivirine for treating HIV in people with viral suppression;</p><p>- Doravirine for treating HIV infection;</p><p>- Vonicog alfa for the treatment of bleeding in adults with von Willebrand disease; and</p><p>- Mercaptamine hydrochloride for treating corneal cystine crystal deposits caused by cystinosis.</p><p>NICE’s work on Ivacaftor for treating cystic fibrosis with a R117H mutation in the CFTR gene is currently paused.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/04/2019 11:41:45 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1105314

	registered interest
	date	26/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health: Disadvantaged
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with his devolved Assembly counterparts on health inequalities throughout the UK.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	237190
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>There have been no recent discussions specifically on health inequalities. However, Ministers frequently engage with counterparts in the devolved administrations.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 02/04/2019 15:53:14 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4131 label Biography information for Jim Shannon

1105315

	registered interest
	date	26/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cervical Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of people being able to self-refer for a smear test in a local sexual health clinic.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	237191
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>The United Kingdom National Screening Committee has made no assessment of the evidence to offer self-referral as part of the National Health Service cervical screening programme. The programme is working with contraception and sexual health clinics to support women who attend for their routine cervical screening, which is offered by some local authorities.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/04/2019 15:40:52 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon